ArticleResearch and practice in thrombosis and haemostasis2020
Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Challenges with measuring tissue factor antigen and activity in human plasma.Blood vessels, thrombosis & hemostasis · 2024Review
- Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.Scientific reports · 2024Article
- Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer.Thrombosis research · 2024Article
- The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024Review
- The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.Journal of thrombosis and haemostasis : JTH · 2023Article
- Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro.Cancers · 2023Article
- Tissue factor activity of small and large extracellular vesicles in different diseases.Research and practice in thrombosis and haemostasis · 2023Article
- Mechanisms of cancer-associated thrombosis.Research and practice in thrombosis and haemostasis · 2023Article
- Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment.Clinical Medicine Insights. Oncology · 2023Review
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
- Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer.Cancer science · 2021Article
- Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer.Cancers · 2021Review
- Cancer Therapy-Associated Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2021Review
- Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
- Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.Blood advances · 2021Article
- Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer.Research and practice in thrombosis and haemostasis · 2020Article
- The Rise of Extracellular Vesicles as New Age Biomarkers in Cancer Diagnosis: Promises and Pitfalls.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
introductionWe conducted a longitudinal study in patients with pancreatic and colorectal cancer. We determined the effect of chemotherapy on extracellular vesicle tissue factor (EVTF) activity and the association of plasma EVTF activity with venous thromboembolism (VTE) and survival. MATERIAL AND
methodsWe enrolled 13 patients with pancreatic and 22 patients with colorectal cancer. Plasma samples were collected during the 85-day study period. Patients were followed for 3 months after the study period. We recorded symptomatic VTE during the study period (3 months) or asymptomatic deep vein thrombosis detected by ultrasound at day 85. We measured EVTF activity before and after chemotherapy. RESULTS AND
conclusionsIn the pancreatic cancer group, 2 patients had elevated levels of EVTF activity. One of these patients developed symptomatic VTE and died, and the second patient did not have a VTE but died. Chemotherapy decreased EVTF activity in 2 pancreatic patients with high levels. In the colorectal cancer group, 4 patients developed VTE, but EVTF activity was not elevated in any patient and no patient died. We observed a borderline significant correlation between EVTF activity and D-dimer in the patients with pancreatic but not colorectal cancer. In this small descriptive study, 2 patients with pancreatic cancer had an elevated level of EVTF activity. Both patients died during the study period, and one had a VTE. Chemotherapy decreased EVTF activity in these patients. In contrast, elevated levels of EVTF activity were not observed in patients with colorectal cancer with or without VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.